학술논문
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Document Type
Article
Author
Gianni, Luca; Pienkowski, Tadeusz; Im, Young-Hyuck; Tseng, Ling-Ming; Liu, Mei-Ching; Lluch, Ana; Starosławska, Elżbieta; de la Haba-Rodriguez, Juan; Im, Seock-Ah; Pedrini, Jose Luiz; Poirier, Brigitte; Morandi, Paolo; Semiglazov, Vladimir; Srimuninnimit, Vichien; Bianchi, Giulia Valeria; Magazzù, Domenico; McNally, Virginia; Douthwaite, Hannah; Ross, Graham; Valagussa, Pinuccia
Source
In The Lancet Oncology June 2016 17(6):791-800
Subject
Language
ISSN
1470-2045